SecBot SecBot
8-K ·Filed Nov 12, 2026

ONCY

ONCOLYTICS BIOTECH INC
NEUTRAL
Impact 3/10
Horizonmonths Processed4d 18h ago SEC0001129928-26-000082
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

The agreement is a low-cost, non-dilutive way to generate early combination data in an indication with no approved second-line therapy. However, the study is exploratory, small-scale, and not registrational. Monitor for patient enrollment updates and any subsequent data readouts that could support a broader HPV-associated cancer strategy.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

ONCY drug pipeline →

pelareorep

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2/3
Time to market
At least 3-5 years (Phase 3 just launching; no BLA/NDA filed)
Next catalyst
None dated

What to watchOncolytics is a single-asset clinical-stage biotech with no approved products. The stock trades at ~$0.92 against a mean analyst price target of ~$4.94 (~5x upside), but the company has limited cash (~$12.4M as of Q3 2025) and has tapped a $75M ATM facility, significant dilution risk. Watch for the Phase 3 pancreatic cancer trial launch (H1 2026) and any anal cancer registration updates, but do not expect a near-term binary catalyst.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.3720
T+0 close · Nov 12, 2026 · via day close
Latest settled
−0.54%
T+1 · $0.3700
Vs SPY
−0.17%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $0.3720entry
  2. T+1 · 4d ago −0.54%α −0.17% · $0.3700
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oncolytics Biotech announced a clinical supply agreement with Coherus Oncology to evaluate its investigational oncolytic virus immunotherapy, pelareorep, in combination with Coherus' PD-1 inhibitor LOQTORZI (toripalimab-tpzi) in a Phase 2 study for second-line squamous cell anal carcinoma (SCAC). The study is expected to begin in Q1 2027 at a U.S. cancer center, with Coherus supplying LOQTORZI. No financial terms were disclosed, and the agreement does not provide near-term revenue or de-risk the development path.

Key Facts

  • Oncolytics entered a clinical supply agreement with Coherus Oncology for a study of pelareorep + LOQTORZI in second-line SCAC patients.
  • Study expected to begin in Q1 2027 at a premier U.S. cancer center.
  • No approved therapy exists for second-line SCAC patients.
  • Coherus will provide LOQTORZI; Oncolytics will partner with the sponsoring institution.
  • No financial terms, milestone payments, or revenue commitments were disclosed.
  • Pelareorep has Fast Track designation from the FDA for colorectal, anal, and pancreatic cancer.

Financial Impact

No financial terms disclosed; non-financial clinical supply agreement.

Risk Factors

  • Study is early-stage and may not yield positive efficacy or safety data.
  • No financial commitment from Coherus beyond drug supply; no milestone or royalty structure.
  • Execution risk: enrollment timeline (Q1 2027) and site activation are uncertain.
  • SCAC is a niche indication; commercial impact depends on expansion to broader HPV-associated cancers.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001129928-26-000082
Document: oncolyticscoherusagmt.htm0001129928-26-000082
Document: 0001129928-26-000082-index-headers.html0001129928-26-000082
Document: 0001129928-26-000082-index.html0001129928-26-000082
Document: 0001129928-26-000082.txt0001129928-26-000082

Track record

32 reports on ONCY

Performance horizon

3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 3/10 Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
  2. Nov 12, 20264d ago 8-K Neutral 3/10 Viewing Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
  3. Nov 11, 20265d ago Press Release Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
  4. Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
  5. Nov 9, 20267d ago Press Release Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
  6. Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
  7. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
  8. Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
  9. Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
  10. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
Showing 10 of 32

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026